MaaT Pharma SA AI Price Prediction

The negative EPS of -2.10 and a corresponding negative PE ratio of -1.52 indicate that MaaT Pharma SA is currently loss-making, with no visible profitability. This is typical for early-stage or R&D-heavy biotech firms, but it still represents fundamental risk for equity holders. Without evidence of improving earnings or a clear path to profitability, the financial profile remains weak.

• Negative EPS (-2.10) signals ongoing net losses and an absence of sustainable profitability.
• Negative PE ratio (-1.52) confirms that the stock is being valued purely on future expectations rather than current earnings power.
• Lack of positive earnings or profitability ratios suggests continued dependence on external financing or capital markets rather than internally generated cash flow.

Despite a 15.4% rise over the last month to €3.19, the stock remains well below its 200-day moving average of €4.82, indicating a longer-term downtrend. The recent bounce appears more like a short-term recovery within a broader bearish structure rather than a confirmed reversal. With price trading under a declining long-term moving average, technical risk remains elevated.

• Current price of €3.19 is significantly below the 200-day moving average of €4.82, a classic sign of a prevailing longer-term downtrend.
• A 15.4% monthly gain suggests short-term positive momentum, but this is not yet sufficient to break the broader bearish technical pattern.
• Without evidence of the price reclaiming and holding above the 200-day moving average, the technical setup remains structurally bearish despite the recent rally.

Overall, MaaT Pharma SA’s stock profile appears bearish, with loss-making fundamentals and a price still well below its 200-day moving average despite a recent rebound. Alternative data are largely neutral and do not provide a strong counterweight to weak earnings and a negative long-term technical trend. Unless there is a clear catalyst for earnings improvement or a sustained technical reversal, risk remains skewed to the downside.

• Persistent negative earnings and a valuation based on future hopes rather than current profitability keep fundamental risk high.
• The stock’s position below its 200-day moving average, despite a recent 15.4% monthly gain, indicates that the longer-term trend is still down and the technical picture remains fragile.